<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2128">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04395794</url>
  </required_header>
  <id_info>
    <org_study_id>CS-COVID-19</org_study_id>
    <nct_id>NCT04395794</nct_id>
  </id_info>
  <brief_title>SARS-CoV-2 Disguise Study</brief_title>
  <acronym>Disguise</acronym>
  <official_title>SARS-CoV-2 Positive Carriers Among Asymptomatic meDIcal employeeS in hiGh-volUme cardIovaScular cEnter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is a pandemic disease
      with worldwide spreading. Limited data are existed regarding SARS-CoV-2 positive carriers
      among asymptomatic medical employees in non-profile infectious clinic, e.g. cardiovascular
      clinic, routinely working in the pandemic region with two million inhabitants. The aim is to
      test the percentage and increase of the SARS-CoV-2 positive carriers among asymptomatic
      medical employees in high-volume cardiovascular center in routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Weeks</target_duration>
  <primary_outcome>
    <measure>SARS-CoV-2 positive test</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of SARS-CoV-2 positive tests and increase of SARS-CoV-2 positive test between 1 st , 2 nd and 3 rd time frame testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transformation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of transformation from asymptomatic SARS-CoV-2 positive carriers to symptomatic form</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors (asymptomatic)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Predictors of the asymptomatic SARS-CoV-2 positive carriers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors (symptomatic)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Predictors of symptomatic form transformation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage from different departments</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of employees from different departments with SARS-CoV-2 positive carriers</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Medical Employees</arm_group_label>
    <description>Asymptomatic medical employees in high-volume cardiovascular center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2-test</intervention_name>
    <description>Nasopharyngeal and oropharyngeal testing for SARS-CoV-2</description>
    <arm_group_label>Medical Employees</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SARS-CoV-2 questionnaire survey</intervention_name>
    <description>Questionnaire regarding SARS-CoV-2 symptoms and contact with COVID patients</description>
    <arm_group_label>Medical Employees</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Asymptomatic medical employees in high-volume cardiovascular center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic medical employees of E. Meshalkin National Medical Research Center of the
             Ministry of Health of the Russian Federation

          -  Filled questionnaire before SARS-CoV-2 testing

          -  Nasopharyngeal and oropharyngeal testing for SARS-CoV-2

          -  Signed informed consent

        Exclusion Criteria:

          -  Unwilling to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander B Romanov, PhD</last_name>
    <phone>+79137172652</phone>
    <email>abromanov@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meshalkin National Medical Research Center</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander B Romanov, PhD</last_name>
      <phone>+79137172652</phone>
      <email>abromanov@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vladimir V Lomivorotov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dmitry N Ponomarev, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis V Losik, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Igor L Mikheenko</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir V Beloborodov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurlan A Elemesov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

